Liraglutide Market Growth Is Reshaping Competitive Advantage Across The Industry
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Liraglutide Market Size Outlook: How Fast Will Revenue Grow Through 2030?
A notable expansion has been observed in the liraglutide market over recent years. Projected figures indicate that between 2025 and 2026, the market is set to rise from $6.88 billion to $7.45 billion, reflecting a compound annual growth rate (CAGR) of 8.2%. Several factors have driven this historical growth, including the increasing worldwide incidence of type 2 diabetes, the demonstrated clinical benefits of GLP-1 receptor agonists, a growing demand for treatments that can manage both blood sugar and body weight, regulatory approvals for liraglutide covering diabetic and weight management indications, and heightened physician trust in injectable incretin-based therapies.
The liraglutide market is anticipated to experience robust expansion over the coming years, reaching a projected value of $10.23 billion by 2030, with a compound annual growth rate (CAGR) of 8.3%. This forecasted growth is driven by factors such as the rising global prevalence of obesity, a growing shift toward weight-focused diabetes treatments, the broadening of metabolic disorder screening initiatives, heightened patient interest in effective appetite-suppressing therapies, and ongoing innovation and education surrounding GLP-1-based treatments. Key trends shaping this period include the widespread integration of liraglutide into type 2 diabetes care, its increasing application in medical weight management, broader acceptance of injectable GLP-1 therapies, the scaling of long-term metabolic disease management programs, and a heightened emphasis on achieving both glycemic control and weight reduction benefits.
Download A Free Sample Report For Comprehensive Market Insights:
Liraglutide Market Industry Drivers: What Is Driving Revenue Growth?
The liraglutide market is anticipated to gain momentum from the expanding number of individuals diagnosed with diabetes worldwide. This condition, characterized by the body’s inability to effectively manage blood glucose levels due to insufficient insulin production or impaired insulin function, continues to rise in prevalence. Its growth is largely attributed to global trends such as sedentary habits, poor dietary choices, and escalating obesity rates. Medications like liraglutide offer therapeutic benefits by replicating the actions of the GLP-1 hormone, which stimulates insulin release, reduces blood sugar, and supports weight reduction, making it a valuable tool for controlling type 2 diabetes. A report by the Government of the United Kingdom, published in March 2024, highlighted that by March 2023, the proportion of patients with type 1 diabetes in England receiving all eight recommended care processes through general practices participating in the NDA had risen to 43.8%, up from 35.2% recorded the prior year. Hence, the ongoing rise in the diabetic population is fueling expansion in the liraglutide market.
Liraglutide Market Segmentation: How Is The Market Structured Across Key Categories?
The liraglutide market covered in this report is segmented –
1) By Brands: Victoza, Saxenda
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies
3) By Type Of Application: Diabetes Treatment, Weight Management
4) By End-Users: Hospitals And Clinics, Homecare Settings
Subsegments:
1) By Victoza: Type 2 Diabetes Treatment Or Weight Management
2) By Saxenda: Weight Loss Treatment Or Obesity Management
Liraglutide Market Growth Trends: What Is Influencing The Future Outlook?
Key players in the liraglutide market are currently concentrating on the creation of innovative products like generic GLP-1 formulations, aiming to broaden the spectrum of therapeutic options and respond to the growing need for more budget-friendly treatments. These generic GLP-1 medications are copies of original GLP-1 receptor agonists, manufactured once patent protection for the branded drugs has lapsed, thereby providing economical alternatives for managing ailments such as type 2 diabetes and obesity. A notable example occurred in June 2024, when Teva Pharmaceutical Industries Ltd., a company headquartered in Israel, launched the debut generic GLP-1 product comparable to Victoza within the U.S. market, thereby catering to the escalating demand for such therapies. These liraglutide injections are utilized to improve glycemic control in adults and children aged ten and above who have type 2 diabetes, as well as to diminish the likelihood of cardiovascular events in adults with type 2 diabetes who also have pre-existing heart conditions.
Liraglutide Market Competitive Landscape And Leading Companies
Major companies operating in the liraglutide market are Novo Nordisk A/S
Access The Complete Liraglutide Market Report:
Liraglutide Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the liraglutide market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
